当前位置：
X-MOL 学术
›
Microb. Drug Resist.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Does Fluoroquinolones and Third-Generation Cephalosporins Restriction Reverse Extended-Spectrum β-Lactamases Klebsiella pneumoniae Resistance Rates?
Microbial Drug Resistance ( IF 2.3 ) Pub Date : 2021-09-09 , DOI: 10.1089/mdr.2020.0301 Mirjana Stanić Benić 1 , Dora Palčevski 2 , Romina Milanič 3 , Nataša Skočibušić 1 , Maja Abram 4, 5 , Vera Vlahović-Palčevski 1, 6, 7
Microbial Drug Resistance ( IF 2.3 ) Pub Date : 2021-09-09 , DOI: 10.1089/mdr.2020.0301 Mirjana Stanić Benić 1 , Dora Palčevski 2 , Romina Milanič 3 , Nataša Skočibušić 1 , Maja Abram 4, 5 , Vera Vlahović-Palčevski 1, 6, 7
Affiliation
Aim: To decrease the incidence and resistance rates of extended-spectrum β-lactamases (ESBL) Klebsiella pneumoniae (KP) by restriction of the use of third-generation cephalosporins (3GCs) and fluoroquinolones.
中文翻译：
氟喹诺酮类和第三代头孢菌素限制是否会逆转超广谱β-内酰胺酶肺炎克雷伯菌耐药率？
目的：通过限制使用第三代头孢菌素（3GCs）和氟喹诺酮类药物，降低超广谱β-内酰胺酶（ESBL）肺炎克雷伯菌（KP）的发生率和耐药率。
更新日期：2021-09-15
中文翻译：
氟喹诺酮类和第三代头孢菌素限制是否会逆转超广谱β-内酰胺酶肺炎克雷伯菌耐药率？
目的：通过限制使用第三代头孢菌素（3GCs）和氟喹诺酮类药物，降低超广谱β-内酰胺酶（ESBL）肺炎克雷伯菌（KP）的发生率和耐药率。
京公网安备 11010802027423号